Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Giovannini, Giada
Orlandi, Niccolò
Brigo, Francesco
Trinka, Eugen
Meletti, Stefano
Article History
Received: 10 June 2023
Revised: 29 July 2023
Accepted: 9 August 2023
First Online: 16 August 2023
Declarations
:
: Simona Lattanzi has received speaker’s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, and Rapport Therapeutics outside the submitted work. Eugen Trinka has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, Böhringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. Eugen Trinka receives Grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union. Eugen Trinka is the CEO of Neuroconsult Ges.m.b.H. Stefano Meletti received research grant support from the Ministry of Health (MOH) and the non-profit organization Foundation “Fondazione Cassa di Risparmio di Modena—FCRM”; has received personal compensation as scientific advisory board member for UCB, Jazz Pharmaceuticals, and EISAI outside the submitted work. The remaining authors have no conflicts of interest.